Tumor uninformed treatment response monitoring assay for research use only
Tempus, a leader in artificial intelligence and precision medicine, announced xF Monitor – a new circulating tumor DNA (ctDNA) assay for research use only, which detects and monitors changes in circulating tumor fraction to determine early response to immunotherapy for patients with advanced cancers.
Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024
Tempus’ xF Monitor assay measures quantitative molecular changes in ctDNA tumor fraction by utilizing diverse genomic events, dynamically weighting somatic variant allele frequencies and copy number variants, while using germline information to inform these estimates. The algorithm that powers xF Monitor – xF ctDNA tumor fraction – utilizes multiple single input models and weights their importance based on failure modes observed in Tempus’ multimodal database. The Tempus team will debut the xF Monitor assay at the Society for Immunotherapy of Cancer’s 38th Annual Meeting this week.
Recommended AI News: NexGen Virtual Empowers Hybrid Workplaces Through Advanced Reporting With Webex by Cisco
“We are excited to add the xF Monitor assay to our comprehensive suite of precision medicine offerings here at Tempus,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “There has been tremendous progress in the utilization of ctDNA for monitoring patient response to treatment, especially for immunotherapy.
Recommended AI News: AWS Announces Amazon EC2 Capacity Blocks for ML Workloads
We are looking forward to bringing our xF Monitor assay forward as a diagnostic tool to help biopharma develop innovative medicines and physicians to tailor therapies for patients.”
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.